TTK protein kinase-derived peptide epitopes presented by HLA-A*24:02 (TTK/HLA-A*24:02)

TTK-derived peptide epitopes presented by HLA-A*24:02 are specific antigenic targets used in the development of cancer immunotherapies, particularly for populations with a high frequency of the HLA-A*24:02 allele. TTK, also known as Monopolar Spindle 1 (MPS1), is a dual-specificity protein kinase essential for the spindle assembly checkpoint during mitosis, ensuring accurate chromosome segregation (UniProt: P33981). Because TTK is overexpressed in a wide range of cancers—including breast, esophageal, and gastric cancers—but has limited expression in normal tissues, it serves as an ideal tumor-associated antigen (PubMed: 18483466). These specific peptides are processed from the TTK protein and presented on the cell surface by the HLA-A*24:02 major histocompatibility complex (MHC) class I molecule. Therapeutic interventions, such as peptide vaccines (e.g., OTS111), aim to stimulate the patient's immune system to produce cytotoxic T lymphocytes (CTLs) that specifically recognize and kill tumor cells displaying these TTK/HLA complexes (PubMed: 24954308). This targeted approach is designed to provide a highly specific anti-tumor response while minimizing damage to healthy cells. Clinical trials have evaluated these epitopes in patients with advanced solid tumors, demonstrating their potential to induce robust immune responses.

Other names

TTK-derived HLA-A*24:02-restricted peptidesMPS1-derived peptide epitopesTTK-567 peptideTTK-A24

Induction of peptide-specific cytotoxic T lymphocytes (CTLs) that recognize and eliminate tumor cells expressing the TTK protein in the context of HLA-A*24:02.